

PATIENT INFORMATION

Please complete the following or send patient demographic sheet

 Patient Name _____
 DOB _____ Last Four of SS# _____ Gender _____
 Address _____
 Home Phone _____ Alternate phone _____
 Legal Guardian name/phone _____
 Language Preference English Spanish Other _____
 Weight _____ lbs. Height _____ in.
 Allergies _____
 Current Medications _____

PRESCRIBER INFORMATION

 Prescriber's Name _____
 NPI _____ DEA _____
 HTC/Group _____
 Hospital Address _____
 City, State, ZIP _____
 Phone _____ Fax _____
 Contact Person _____ Phone _____

INSURANCE INFORMATION (Must submit a copy of patient's insurance card including both sides)

 Primary insurance name: _____ ID number: _____ BIN: _____ PCN: _____ Group: _____
 Secondary insurance name: _____ ID number: _____ BIN: _____ PCN: _____ Group: _____
 Prior Authorization Reference number _____

CLINICAL INFORMATION

Diagnosis — Please include diagnosis name with ICD-10 code

 D66 Hereditary factor VIII deficiency D67 Hereditary factor IX deficiency
 D68.24 Hereditary factor X deficiency Other Diagnosis: ICD-10 Code _____
 Next Infusion Date _____ Access: Port PIV PICC Other: _____
 Target Joints: No Yes _____
 Protocol: Pre-Surgical Continuous Prophylaxis Immune Tolerance

Additional Information

 Therapy: New Reauthorization Restart
 Factor Deficiency: Severe (<1%) Moderate (1-5%) Mild (>5%)
 History of inhibitor: No Yes
 Tolerized? No Yes N/A
 Nursing needed? No Yes Frequency of nursing _____

PRESCRIPTION INFORMATION

Medication

 Advate® Adynovate® Afstyla® Alphanate® AlphaNine® SD Alprolix® Benefix® Corifact® Elocate®
 Esperoct® Feiba® Helixate® FS Hemlibra® Hemofil M® Humate P® Idelvion® Ixinity® Jivi®
 Koate® Koate® DVI Kovaltry® Monoclate® P Mononine® NovoEight® NovoSeven® RT Nuwiq® Profilnine®
 Rebinyn® Recombinate® Riastap® Rixubis® Sevenfact® Tretten® Vonvendi® Wilate® Xyntha®
 Xyntha® Solofuse Other

Dose / Strength*	Directions	Quantity	Refills

* Unless otherwise directed, pharmacy will dispense clotting factor within a range of +/- 10% of the prescribed dose, per MASAC guidelines.

Other Prescriptions	Dose / Strength	Directions	Quantity	Refills
<input type="checkbox"/> Sodium Chloride flushes	0.9%	Flush IV with 5 to 10 mL of 0.9% sodium chloride, pre and/or post infusion, as directed.		
<input type="checkbox"/> Heparin flushes				
<input type="checkbox"/> Epipen® or <input type="checkbox"/> Epipen Jr.®		Inject as directed IM/SC if needed for anaphylaxis. May repeat in 5 to 15 minutes, if needed.	2	
<input type="checkbox"/> Lidocaine/Prilocaine topical cream	2.5%/2.5%	Apply topically to affected site 30 to 60 minutes prior to infusion.	30 grams	
<input type="checkbox"/> Amicar® tablet <input type="checkbox"/> Amicar® solution				
<input type="checkbox"/> Lysteda®	650 mg tablets			
<input type="checkbox"/> Desmopressin nasal spray	150 mcg/actuation			

Ancillary supplies will be provided as needed for medication administration and disposal, unless otherwise noted:

Prescriber Authorization: I authorize the pharmacy and its representatives to act as my authorized agent to secure coverage and initiate the insurance prior authorization process for my patient(s), and to sign any necessary forms on my behalf as my authorized agent, including the receipt of any required prior authorization forms and the receipt and submission of patient lab values and other patient data. In the event that this pharmacy determines that it is unable to fulfill this prescription, I further authorize this pharmacy to forward this information and any related materials related to coverage of the product to another pharmacy of the patient's choice or in the patient's insurer's provider network.

Ship to: Patient Office Other _____

Prescriber's Signature _____ Date _____ Needs by Date _____

Electronic or digital signatures not accepted.

Substitution is allowed unless the prescriber indicates "Brand Medically Necessary"

NY and IA providers, please submit electronic prescription for medication and needles, if needed.
CONFIDENTIALITY STATEMENT: This communication is intended for the use of the individual or entity to which it is addressed and may contain information that is privileged, confidential, and exempt from disclosure under applicable law. If the reader of this communication is not the intended recipient or the employee or agent responsible for delivery of the communication, you are hereby notified that any dissemination, distribution, or copying of the communication is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone.